Slovakia Pharmaceuticals & Healthcare Report Q4 2014
Headline Expenditure Projections
- Pharmaceuticals: EUR1.67bn (USD2.20bn) in 2013 to EUR1.68bn (USD2.13bn) in 2014; 0.6% in local currency terms and -3.2% in US dollar terms. Figures in line with Q314 forecast.
- Healthcare: EUR6.00bn (USD7.92bn) in 2013 to EUR6.07bn (USD7.71bn) in 2014; 1.2% in local currency terms and -2.6% in US dollar terms. Figures in line with Q314 forecast.
Slovakia's Risk rating indicates the country has one of the best business environments in the Central and Eastern European region, although its ranking is moderated by its less-than-stellar rewards score. Consequently, Slovakia has a RRR score of 55.2 out of 100, making it now the sixth most attractive pharmaceutical market in Central and Eastern Europe. This means the country has remained in the same position as in Q314.
Key Trends And Developments
In June 2014, the Slovakian health ministry has imposed a fine of EUR10,000 (USD13,619) each on two companies for the non-availability of medicines. The fines were imposed following a shortage of medicines for high cholesterol and epilepsy in the market. The ministry has imposed total fines of EUR70,000...
The Slovakia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Slovakia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Slovak pharmaceutical and healthcare industry.
- Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Slovakia to test other views - a key input for successful budgeting and strategic business planning in the Slovak pharmaceutical and healthcare market.
- Target business opportunities and risks in the Slovak pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Slovakia.
- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
BMI Industry View & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.
BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)
Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)
OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
The Slovakian health ministry has introduced orders to reign in medical fees charged by doctors and outpatient physician, with rules set to enter effect from autumn this year. Medical fees by hospitals and doctors are symptomatic of the chronic inefficiency of healthcare funding within Slovakia. With the healthcare system set to come under the complete control of the Slovak state, funding issues will be resolved, but this will also have potential negative implications for the pharmaceuticals and healthcare sector, as the state will hold significant leverage and out of pocket payments are still high. Nevertheless, Slovakia continues to be an attractive pharmaceutical market for large multi-nationals because it generally offers significant potential as a location for pharmaceutical research.
BMI Industry View
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Slovakia 2010-2018)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2010-2018)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2010-2018)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2010-2018)
Prescription Drug Market Forecast
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Slovakia 2010-2018)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Slovakia 2010-2018)
Table: Members Of GENAS, 2011
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Slovakia 2010-2018)
OTC Medicine Market Forecast
Table: Leading Prescription Medicines In Slovakia, By 2011 Volume
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Slovakia 2010-2018)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Slovakia 2012-2018)
Table: Pharmaceutical Trade Data And Forecasts local currency (Slovakia 2012-2018)
Other Healthcare Data
Key Risks To BMI's Forecast Scenario
Table: Slovakia - GDP By Expenditure
Industry Risk Reward Ratings
Central And Eastern Europe Risk/Reward Ratings
Slovakia Risk/Reward Ratings
Industry Trends And Developments
Table: Main Causes Of Mortality And Morbidity In Slovakia
Recent Healthcare Sector Developments
Private Health Insurance
Recent Health Insurance Developments
Research And Development
Table: Members Of BITCET, 2011
Table: Members Of SLOVBIOTECH, 2010
Pharmaceutical Promotion And Advertising
Marketing Authorisation Regime
Intellectual Property Regime
Table: Indexed Price Build-Up For Prescription And Non-Prescription Medicines In Slovakia
Table: Registered Pharmaceutical Manufacturers
Table: Members Of SAFS, 2012
Table: ADL Members, 2012 (Manufacturers, unless otherwise indicated)
Merck & Co
Table: Slovakia's Population By Age Group, 1990-2020 ('000)
Table: Slovakia's Population By Age Group, 1990-2020 (% of total)
Table: Slovakia's Key Population Ratios, 1990-2020
Table: Slovakia's Rural And Urban Population, 1990-2020
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Ratings Methodology
Table: Pharmaceutical Risk/Reward Ratings Indicators
This report does not have a list of Companies Mentioned available
This report does not have a press release associated with it